Targeting immunosuppression for cancer therapy
Cristina Ghirelli, Thorsten Hagemann
Cristina Ghirelli, Thorsten Hagemann
Published May 24, 2013
Citation Information: J Clin Invest. 2013;123(6):2355-2357. https://doi.org/10.1172/JCI69999.
View: Text | PDF
Commentary

Targeting immunosuppression for cancer therapy

Abstract

Failing immunity has been acknowledged for its contribution to cancer development and progression. Recent clinical findings have provided payoffs for significant preclinical evaluation and refinement over the last 20 years, but many questions remain to be answered. In this issue of the JCI, Marabelle et al. describe a novel method for targeting the Tregs that infiltrate tumors, demonstrating that dampening the tumor immunosuppressive environment while activating innate antitumor immunity may be an effective approach to cancer treatment.

Authors

Cristina Ghirelli, Thorsten Hagemann

×

Figure 1

Marabelle et al. showed how local immunotherapy in mice helps the eradication of tumors at distant sites, even in an immune-privileged site such as the brain.

Options: View larger image (or click on image) Download as PowerPoint
Marabelle et al. showed how local immunotherapy in mice helps the eradic...
This study opens several questions, and how these findings may translate to human immunotherapy is still a matter of debate.